[go: up one dir, main page]

WO2004007676A3 - Combination therapy for the treatment of neoplasms - Google Patents

Combination therapy for the treatment of neoplasms Download PDF

Info

Publication number
WO2004007676A3
WO2004007676A3 PCT/US2003/021783 US0321783W WO2004007676A3 WO 2004007676 A3 WO2004007676 A3 WO 2004007676A3 US 0321783 W US0321783 W US 0321783W WO 2004007676 A3 WO2004007676 A3 WO 2004007676A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasms
treatment
combination therapy
neoplasm
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/021783
Other languages
French (fr)
Other versions
WO2004007676A2 (en
Inventor
Margaret S Lee
Curtis Keith
Benjamin A Auspitz
Grant R Zimmermann
M James Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CombinatoRx Inc filed Critical CombinatoRx Inc
Priority to AU2003251875A priority Critical patent/AU2003251875A1/en
Publication of WO2004007676A2 publication Critical patent/WO2004007676A2/en
Publication of WO2004007676A3 publication Critical patent/WO2004007676A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) ciclopirox or structural or functional analogs thereof; and optionally (ii) an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.
PCT/US2003/021783 2002-07-15 2003-07-14 Combination therapy for the treatment of neoplasms Ceased WO2004007676A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003251875A AU2003251875A1 (en) 2002-07-15 2003-07-14 Combination therapy for the treatment of neoplasms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39612002P 2002-07-15 2002-07-15
US60/396,120 2002-07-15
US40090502P 2002-08-02 2002-08-02
US60/400,905 2002-08-02

Publications (2)

Publication Number Publication Date
WO2004007676A2 WO2004007676A2 (en) 2004-01-22
WO2004007676A3 true WO2004007676A3 (en) 2004-04-08

Family

ID=30118565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021783 Ceased WO2004007676A2 (en) 2002-07-15 2003-07-14 Combination therapy for the treatment of neoplasms

Country Status (2)

Country Link
AU (1) AU2003251875A1 (en)
WO (1) WO2004007676A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456269A1 (en) * 2001-08-23 2003-03-06 The Government Of The United States Of America Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
EP1696917A1 (en) * 2003-12-19 2006-09-06 Novartis AG COMBINATION OF (a) N-{5- [4-(4-METHYL-PIPERAZINO-METHYL) -BENZOYLAMIDO] -2METHYLPHENYL]-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
JP5401849B2 (en) * 2008-06-30 2014-01-29 山陽色素株式会社 Pigment dispersion for color filters
US20110212176A1 (en) * 2008-10-31 2011-09-01 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
AU2011261501B2 (en) * 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
CN104945318A (en) 2010-06-01 2015-09-30 拜欧赛里克斯公司 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
IT1405078B1 (en) * 2010-06-23 2013-12-16 Quattrone COMPOUNDS FOR THE TREATMENT OF TUMORS WHICH CARRY MYC DEREGOLATE ONCOPROTEINS
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
ES2836208T3 (en) * 2014-11-11 2021-06-24 Univ Kansas Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
US10085979B2 (en) 2014-12-02 2018-10-02 Ignyta, Inc. Combinations for the treatment of neuroblastoma
JP7061068B2 (en) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド Combination drug for cancer treatment
KR102718538B1 (en) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 Pharmaceutical composition comprising entrectinib
CN111225662B (en) 2017-10-17 2022-11-22 伊尼塔公司 Pharmaceutical compositions and dosage forms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
US6277892B1 (en) * 1991-10-16 2001-08-21 Schering-Plough Healthcare Products, Inc. Enhanced skin penetration system for improved topical delivery of drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US6277892B1 (en) * 1991-10-16 2001-08-21 Schering-Plough Healthcare Products, Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death

Also Published As

Publication number Publication date
AU2003251875A1 (en) 2004-02-02
WO2004007676A2 (en) 2004-01-22
AU2003251875A8 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2005027842A8 (en) Combinations of drugs for the treatment of neoplasms
WO2001066103A3 (en) Treatment of neoplasms by inhalation of carboplatin
MXPA03003960A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders.
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
DE60324427D1 (en) METHOD FOR MODULATING TUBULINDEACETYLASE ACTIVITY
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
BR0207443A (en) Method and dosage form for the treatment of tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.
ATE344662T1 (en) AGENTS CONTAINING N-CHLORTAURINE AND THEIR USE FOR THE TREATMENT OF MUCOUS POLYPS
ATE545423T1 (en) AGENTS FOR THE TREATMENT OF LUNG CANCER
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP